Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

NCT04567329 is registered in ClinicalTrials.gov with Bausch & Lomb Incorporated as lead sponsor.

NCT NCT04567329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04567329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Lead sponsor
Bausch & Lomb Incorporated
Phase
Phase 3
Overall status
Completed
Start date
November 18, 2020
Completion date
August 30, 2021
Enrollment
620 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease